Elanco appoints Stacey Ma to board; board expands to 15 members

Elanco Animal Health Inc

Ma appointed effective Nov 11, 2024; board increased from 14 to 15 directors.
Ma will serve on Innovation, Science and Technology Committee.
Ma is EVP of Pharmaceutical Development and Manufacturing at Gilead Sciences.
Her expertise in CMC and drug development supports Elanco's IPP strategy.
No related party transactions or arrangements in her appointment.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stacey Ma

Director

ELAN · Elanco Animal Health Inc

Effective: 2024-11-11
Filed: November 12, 2024, 6:59 PM ET

On November 11, 2024, the Board of Directors (the “Board”) of Elanco Animal Health Incorporated (the “Company”) appointed Stacey Ma, PhD, to the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stacey Ma was appointed as Director at Elanco Animal Health Inc.

Action: appointed
Role: Director

Exact text from the filing

On November 11, 2024, the Board of Directors (the “Board”) of Elanco Animal Health Incorporated (the “Company”) appointed Stacey Ma, PhD, to the Board

View on SEC.gov

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-24-116942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.